🇺🇸 FDA
Pipeline program

REGN2810/ipi

R2810-ONC-16111

Phase 3 small_molecule terminated

Quick answer

REGN2810/ipi for Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Non-small Cell Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials